Clinical efficacy of carrellizumab combined with albumin-bound paclitaxel in patients with locally advanced esophageal cancer

doi:10.11958/20240622

Abstract

Abstract:

Objective To explore the clinical effect and safety of carrellizumab combined with albumin-bound paclitaxel on the treatment of patients with locally advanced esophageal cancer. Methods Ninety-eight patients with locally advanced esophageal cancer were randomly divided into the study group and the reference group, with 49 cases in each group. The reference group was treated with albumin-bound paclitaxel, while the study group was treated with camrelizumab+albumin-bound paclitaxel. After treatment, the overall efficacy was evaluated, and the disease control rate was calculated. Serum tumor markers [high mobility group protein B1 (HMGB1), squamous cell carcinoma associated antigen (SCCA)], PD-1 and PD-L1 levels were detected by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Immunohistochemistry was used to detect the microvascular density (MVD) and the expression levels of PD-1 and PD-L1 in esophageal carcinoma tissue. The percentages of CD3^＋, CD4^＋and CD8^＋cells were detected by flow cytometry. Patients were followed up and adverse reactions and survival were recorded. Results The disease control rate was higher in the study group than that of the control group (P<0.05). There were no significant differences in all indexes between the groups before treatment (P>0.05). After treatment, HMGB1 level, SCCA level, MVD, serum PD-1 level and tumor tissue high expression rate of PD-1 were all decreased in the two groups, while serum PD-L1 level, PD-L1 high expression rate and percentages of CD3^＋, CD4^＋ and CD8^＋cells were all increased (P<0.05). Except there was no significant difference in MVD between groups, the other indexes were significantly changed in the study group compared with the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The progression-free survival rate was higher in the study group than that of the control group (P<0.05). Conclusion Carrellizumab combined with albumin-bound paclitaxel in the treatment of locally advanced esophageal cancer can help control lesion progression and inhibit angiogenesis, with good safety.

Key words: esophageal neoplasms, microvascular density, albumin-bound paclitaxel, camrelizumab

CLC Number:

R735.1

Figures/Tables 8

References 23

[1]	THAKUR B, DEVKOTA M, CHAUDHARY M. Management of locally advanced esophageal cancer[J]. JNMA J Nepal Med Assoc, 2021, 59(236):409-416. doi:10.31729/jnma.4299.
[2]	WATANABE S, OGINO I, KUNISAKI C, et al. Sequential chemotherapy after definitive radiotherapy in markedly elderly patients with advanced esophageal cancer[J]. Indian J Cancer, 2022, 59(2):244-250. doi:10.4103/ijc.IJC_768_19.
[3]	JIANG H, LI Q, CHEN B, et al. Phase I study of cisplatin and nanoparticle albumin-bound-paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma[J]. Cancer Med, 2023, 12(14):15187-15198. doi:10.1002/cam4.6205.
[4]	JI Y, DU X, ZHU W, et al. Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer:a multicenter randomized phase 3 clinical trial[J]. JAMA Oncol, 2021, 7(10):1459-1466. doi:10.1001/jamaoncol.2021.2705.
[5]	LI J, MA S. History and current situation of neoadjuvant treatment for locally advanced esophageal cancer[J]. Thorac Cancer, 2021, 12(17):2293-2299. doi:10.1111/1759-7714.14069.
[6]	LIU J, YANG Y, LIU Z, et al. Multicenter,single-arm,phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma[J]. J Immunother Cancer, 2022, 10(3):e004291. doi:10.1136/jitc-2021-004291.
[7]	杨日辉, 廖玉婷, 范伟雄, 等. 基于MRI影像组学模型对食管癌淋巴结转移的预测价值[J]. 国际医学放射学杂志, 2022, 45(6): 626-631.
	YANG R H, LIAO Y T, FAN W X, et al. Predictive value of MRI radiomics models for lymph node metastasis in patients with esophageal cancer[J]. Int J Med Radiol, 2022, 45(6): 626-631. doi:10.19300/j.2022.L19528.
[8]	WANG S, LI Y, LIU Z, et al. Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer:A network meta-analysis[J]. Lung Cancer, 2023, 178(1):47-56. doi:10.1016/j.lungcan.2023.02.003.
[9]	中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南[M]. 北京: 中国协和医科大学出版社, 2013:104-107.
	Esophageal Cancer Professional Committee of Chinese Anticancer Association. Clinical practice guidelines for the diagnosis and treatment of esophageal cancer[M]. Beijing: Beijing Union Medical University Press, 2013:104-107.
[10]	丁永为. 实体瘤WHO疗效标准与对数杀灭定量评价的探讨[J]. 临床肿瘤学杂志, 2005, 10(4):384-387.
	DING Y W. The correlation of WHO criteria with the log cell kill quantitative determine[J]. Chinese Clinical Oncology, 2005, 10(4):384-387. doi:10.3969/j.issn.1009-0460.2005.04.015.
[11]	MU C Y, HUANG J A, CHEN Y, et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation[J]. Med Oncol, 2011, 28(3):682-688. doi:10.1007/s12032-010-9515-2.
[12]	HARADA K, ROGERS J E, IWATSUKI M, et al. Recent advances in treating oesophageal cancer[J]. F1000Res, 2020, 9(1):1-9. doi:10.12688/f1000research.22926.1.
[13]	YANG Y, LI H, CHEN X, et al. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma[J]. Thorac Cancer, 2023, 14(7):700-708. doi:10.1111/1759-7714.14795.
[14]	王希龙, 修家伟, 李旭, 等. 卡瑞利珠单抗联合白蛋白紫杉醇+顺铂化疗用于局部晚期食管癌术前新辅助治疗临床效果观察[J]. 临床军医杂志, 2022, 50(8):806-809,813.
	WANG X L, XIU J W, LI X, et al. Clinical study of carrelizumab combined with albumin-bound paclitaxel and cisplatin in preoperative neoadjuvant therapy for locally advanced esophageal cancer[J]. Clinical Journal of Medical Officers, 2022, 50(8):806-809,813. doi:10.16680/j.1671-3826.2022.08.09.
[15]	LI Y, ZHOU A, LIU S, et al. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC:a randomized Phase II clinical trial :A randomized clinical trial of neoadjuvant therapy for ESCC[J]. BMC Med, 2023, 21(1):86-97. doi:10.1186/s12916-023-02804-y.
[16]	胡加海, 薛松, 陈荃. 卡瑞利珠单抗联合化疗方案对中晚期食管癌患者血清miR-21、可溶性E-钙黏蛋白表达的影响[J]. 天津医药, 2022, 50(8):873-878.
	HU J H, XUE S, CHEN Q. Effects of camrelizumab combined with chemotherapy on serum miR-21 and soluble E-cadherin in patients with advanced esophageal cancer[J]. Tianjin Med J, 2022, 50(8):873-878. doi:10.11958/20220150.
[17]	CHEN F, QIU L, MU Y, et al. Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma[J]. Front Surg, 2022, 9(1):1-8. doi:10.3389/fsurg.2022.893372.
[18]	GUO X, MENG X, LIU R. Prognostic value of microvessel density in esophageal squamous cell carcinoma-a systematic review and meta-analysis[J]. Pathol Res Pract, 2021, 227(1):1-11. doi:10.1016/j.prp.2021.153644.
[19]	马秀梅, 席俊峰, 张世达. 食管癌磁共振成像表现与微血管密度和预后的关系[J]. 中国肿瘤临床与康复, 2021, 28(11):1345-1348.
	MA X M, XI J F, ZHANG S D. Association between MRI manifestations and micro vessel density and prognosis in patients with esophageal cancer[J]. Chinese Journal of Clinical Oncology and Rehabilitation, 2021, 28(11):1345-1348. doi:10.13455/j.cnki.cjcor.2021.11.17.
[20]	YANG Y, ZHANG J, MENG H, et al. Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma:a single-arm phase 2 study (cohort study)[J]. Int J Surg, 2024, 110(3):1430-1440. doi:10.1097/JS9.0000000000000978.
[21]	WU S Y, XU Y, CHEN L, et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC:concept exploration and biomarker analysis in the FUTURE-C-Plus trial[J]. Mol Cancer, 2022, 21(1):84-98. doi:10.1186/s12943-022-01536-6.
[22]	KAM N W, WU K C, DAI W, et al. Peritumoral B cells drive proangiogenic responses in HMGB1-enriched esophageal squamous cell carcinoma[J]. Angiogenesis, 2022, 25(2):181-203. doi:10.1007/s10456-021-09819-0.
[23]	ZHU H. Squamous cell carcinoma antigen:clinical application and research status[J]. Diagnostics(Basel), 2022, 12(5):1065-1680. doi:10.3390/diagnostics12051065.

组别		n	性别（男/女）		年龄/ 岁	BMI/ （kg/m²）			疾病分型（鳞癌/腺癌）
对照组		49	23/26		60.20±5.81	23.29±1.17			35/14
研究组		49	27/22		59.60±5.64	23.16±1.39			33/16
t或χ²			0.653		0.529	0.537			0.192
组别	分期（Ⅲ期/Ⅳ期）			肿瘤直径/ cm			肿瘤位置
组别	分期（Ⅲ期/Ⅳ期）			肿瘤直径/ cm			颈段	上段		中段	下段
对照组	30/19			8.22±1.69			13	11		16	9
研究组	34/15			8.39±1.44			8	15		14	12
t或χ²	0.721			0.515			2.368

组别		n	性别（男/女）		年龄/ 岁	BMI/ （kg/m²）			疾病分型（鳞癌/腺癌）
对照组		49	23/26		60.20±5.81	23.29±1.17			35/14
研究组		49	27/22		59.60±5.64	23.16±1.39			33/16
t或χ²			0.653		0.529	0.537			0.192
组别	分期（Ⅲ期/Ⅳ期）			肿瘤直径/ cm			肿瘤位置
组别	分期（Ⅲ期/Ⅳ期）			肿瘤直径/ cm			颈段	上段		中段	下段
对照组	30/19			8.22±1.69			13	11		16	9
研究组	34/15			8.39±1.44			8	15		14	12
t或χ²	0.721			0.515			2.368

组别	n	CR	PR	SD	PD	疾病控制
对照组	49	9（18.37）	20（40.82）	8（16.33）	12（24.49）	37（75.51）
研究组	49	15（30.61）	19（38.78）	11（22.45）	4（8.16）	45（91.84）

组别	n	CR	PR	SD	PD	疾病控制
对照组	49	9（18.37）	20（40.82）	8（16.33）	12（24.49）	37（75.51）
研究组	49	15（30.61）	19（38.78）	11（22.45）	4（8.16）	45（91.84）

组别	HMGB1/（μg/L）			SCCA/（μg/L）			MVD/（个/视野）
组别	治疗前	治疗后	t	治疗前	治疗后	t	治疗前	治疗后	t
对照组	257.54±30.88	126.92±22.43	26.692^＊	6.16±1.27	5.41±1.29	2.742^＊	15.82±3.10	13.53±2.61	3.604^＊
研究组	255.62±32.67	98.51±19.32	25.784^＊	6.14±1.26	3.37±0.84	12.683^＊	15.67±2.39	13.39±2.14	5.409^＊
t	0.297	6.718^＊		0.078	9.198^＊		0.255	0.297